Home/Pipeline/DYNE-101

DYNE-101

Myotonic Dystrophy Type 1 (DM1)

Phase 1/2ActiveNCT06261027 (ACHIEVE)

Key Facts

Indication

Myotonic Dystrophy Type 1 (DM1)

Phase

Phase 1/2

Status

Active

Company

Dyne Therapeutics

About Dyne Therapeutics

Dyne Therapeutics is executing a focused strategy to become a leader in precision genetic medicine for muscle diseases. The company's core achievement is the development of its FORCE™ platform, an antibody-oligonucleotide conjugate technology designed for muscle-specific delivery, which has now propelled three lead candidates into clinical trials. Its strategy targets large, validated genetic indications—myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD)—with the goal of demonstrating superior efficacy and tolerability. With a cash runway extending into 2026, Dyne is well-positioned to generate critical clinical proof-of-concept data across its pipeline.

View full company profile

Therapeutic Areas

Neuromuscular Diseases Genetic Disorders

Other Myotonic Dystrophy Type 1 (DM1) Drugs

Drug	Company	Phase	Status
ATX-01 (ArthemiR trial)	ARTHEx Biotech	Phase 1/2	Active
AOC 1001	Avidity Biosciences	Phase 1/2	Active
SRP-6004	Sarepta Therapeutics	Phase 1/2	Active (siRNA); First clinical data 2026
Undisclosed	Design Therapeutics	Preclinical	Active
PGN-EDODM1	PepGen	Phase 2	Recruiting